company background image
2269

WuXi Biologics (Cayman)SEHK:2269 Stock Report

Market Cap

HK$499.5b

7D

-4.3%

1Y

99.3%

Updated

25 Sep, 2021

Data

Company Financials +
2269 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

2269 Overview

WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People’s Republic of China, North America, Europe, and internationally.

WuXi Biologics (Cayman) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for WuXi Biologics (Cayman)
Historical stock prices
Current Share PriceHK$117.80
52 Week HighHK$59.07
52 Week LowHK$148.00
Beta1.08
1 Month Change0.77%
3 Month Change-17.22%
1 Year Change99.32%
3 Year Change346.49%
5 Year Changen/a
Change since IPO1,150.97%

Recent News & Updates

Shareholder Returns

2269HK Life SciencesHK Market
7D-4.3%-4.6%-2.4%
1Y99.3%99.1%9.1%

Return vs Industry: 2269 matched the Hong Kong Life Sciences industry which returned 99.1% over the past year.

Return vs Market: 2269 exceeded the Hong Kong Market which returned 9.1% over the past year.

Price Volatility

Is 2269's price volatile compared to industry and market?
2269 volatility
2269 Beta1.08
Industry Beta1.1
Market Beta1

Stable Share Price: 2269 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 2269's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20147,686Chris Chenhttps://www.wuxibiologics.com

WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People’s Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd.

WuXi Biologics (Cayman) Fundamentals Summary

How do WuXi Biologics (Cayman)'s earnings and revenue compare to its market cap?
2269 fundamental statistics
Market CapCN¥414.85b
Earnings (TTM)CN¥2.79b
Revenue (TTM)CN¥8.08b

148.4x

P/E Ratio

51.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2269 income statement (TTM)
RevenueCN¥8.08b
Cost of RevenueCN¥4.04b
Gross ProfitCN¥4.04b
ExpensesCN¥1.24b
EarningsCN¥2.79b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.66
Gross Margin49.97%
Net Profit Margin34.61%
Debt/Equity Ratio9.6%

How did 2269 perform over the long term?

See historical performance and comparison

Valuation

Is WuXi Biologics (Cayman) undervalued compared to its fair value and its price relative to the market?

148.43x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 2269 (HK$117.8) is trading above our estimate of fair value (HK$108.27)

Significantly Below Fair Value: 2269 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 2269 is poor value based on its PE Ratio (148.4x) compared to the Hong Kong Life Sciences industry average (45.5x).

PE vs Market: 2269 is poor value based on its PE Ratio (148.4x) compared to the Hong Kong market (9.6x).


Price to Earnings Growth Ratio

PEG Ratio: 2269 is poor value based on its PEG Ratio (5.1x)


Price to Book Ratio

PB vs Industry: 2269 is overvalued based on its PB Ratio (12.5x) compared to the HK Life Sciences industry average (6.6x).


Future Growth

How is WuXi Biologics (Cayman) forecast to perform in the next 1 to 3 years based on estimates from 26 analysts?

29.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2269's forecast earnings growth (29.3% per year) is above the savings rate (1.5%).

Earnings vs Market: 2269's earnings (29.3% per year) are forecast to grow faster than the Hong Kong market (17.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 2269's revenue (32.7% per year) is forecast to grow faster than the Hong Kong market (12.3% per year).

High Growth Revenue: 2269's revenue (32.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2269's Return on Equity is forecast to be low in 3 years time (16.7%).


Past Performance

How has WuXi Biologics (Cayman) performed over the past 5 years?

54.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2269 has a high level of non-cash earnings.

Growing Profit Margin: 2269's current net profit margins (34.6%) are higher than last year (30.1%).


Past Earnings Growth Analysis

Earnings Trend: 2269's earnings have grown significantly by 54.5% per year over the past 5 years.

Accelerating Growth: 2269's earnings growth over the past year (115%) exceeds its 5-year average (54.5% per year).

Earnings vs Industry: 2269 earnings growth over the past year (115%) exceeded the Life Sciences industry 57.3%.


Return on Equity

High ROE: 2269's Return on Equity (8.5%) is considered low.


Financial Health

How is WuXi Biologics (Cayman)'s financial position?


Financial Position Analysis

Short Term Liabilities: 2269's short term assets (CN¥22.0B) exceed its short term liabilities (CN¥5.4B).

Long Term Liabilities: 2269's short term assets (CN¥22.0B) exceed its long term liabilities (CN¥4.6B).


Debt to Equity History and Analysis

Debt Level: 2269's debt to equity ratio (9.6%) is considered satisfactory.

Reducing Debt: 2269's debt to equity ratio has reduced from 384.6% to 9.6% over the past 5 years.

Debt Coverage: 2269's debt is well covered by operating cash flow (69.5%).

Interest Coverage: 2269 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is WuXi Biologics (Cayman) current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2269's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2269's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2269's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2269's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2269's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Chris Chen (48 yo)

5.67yrs

Tenure

CN¥31,365,000

Compensation

Dr. Zhisheng Chen, also known as Chris, has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr. Chen i...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD4.85M) is above average for companies of similar size in the Hong Kong market ($USD1,000.00K).

Compensation vs Earnings: Chris's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 2269's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: 2269's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.


Top Shareholders

Company Information

WuXi Biologics (Cayman) Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: WuXi Biologics (Cayman) Inc.
  • Ticker: 2269
  • Exchange: SEHK
  • Founded: 2014
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$499.483b
  • Shares outstanding: 4.24b
  • Website: https://www.wuxibiologics.com

Number of Employees


Location

  • WuXi Biologics (Cayman) Inc.
  • No. 108, Meiliang Road
  • Mashan
  • Wuxi
  • Jiangsu Province
  • 214092
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 10:03
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.